40.37
0.89 (2.25%)
| Previous Close | 39.48 |
| Open | 40.63 |
| Volume | 576,691 |
| Avg. Volume (3M) | 636,593 |
| Market Cap | 2,194,182,144 |
| Price / Earnings (TTM) | 34.80 |
| Price / Earnings (Forward) | 20.33 |
| Price / Sales | 1.76 |
| Price / Book | 1.66 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 - 5 May 2025 |
| Profit Margin | 5.05% |
| Operating Margin (TTM) | 11.05% |
| Diluted EPS (TTM) | 1.16 |
| Quarterly Revenue Growth (YOY) | 3.80% |
| Quarterly Earnings Growth (YOY) | 242.10% |
| Total Debt/Equity (MRQ) | 51.26% |
| Current Ratio (MRQ) | 2.88 |
| Operating Cash Flow (TTM) | 183.04 M |
| Levered Free Cash Flow (TTM) | 143.42 M |
| Return on Assets (TTM) | 4.19% |
| Return on Equity (TTM) | 4.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | LivaNova PLC | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -4.0 |
| Average | 1.38 |
|
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 0.33% |
| % Held by Institutions | 104.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 64.00 (Needham, 58.53%) | Buy |
| Median | 60.00 (48.63%) | |
| Low | 55.00 (Goldman Sachs, 36.24%) | Buy |
| Average | 59.00 (46.15%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 41.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 17 Mar 2025 | 64.00 (58.53%) | Buy | 41.41 |
| 26 Feb 2025 | 64.00 (58.53%) | Buy | 41.45 | |
| Barclays | 07 Mar 2025 | 56.00 (38.72%) | Hold | 39.17 |
| Goldman Sachs | 03 Mar 2025 | 55.00 (36.24%) | Buy | 41.72 |
| Mizuho | 26 Feb 2025 | 60.00 (48.63%) | Buy | 41.45 |
| Stifel | 26 Feb 2025 | 60.00 (48.63%) | Buy | 41.45 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Mar 2025 | Announcement | LivaNova to Announce First-Quarter 2025 Results |
| 25 Feb 2025 | Announcement | LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance |
| 21 Feb 2025 | Announcement | LivaNova to Present at the Barclays Global Healthcare Conference |
| 21 Jan 2025 | Announcement | LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results |
| 06 Jan 2025 | Announcement | LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |